An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

This randomized, open‐label, active‐controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long‐acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacirca, Jeffrey L., Chan, Arlene, Mezei, Klára, Adoo, Clarence S., Pápai, Zsuzsanna, McGregor, Kimberly, Okera, Meena, Horváth, Zsolt, Landherr, László, Hanslik, Jerzy, Hager, Steven J., Ibrahim, Emad N., Rostom, Makharadze, Bhat, Gajanan, Choi, Mi Rim, Reddy, Guru, Tedesco, Karen L., Agajanian, Richy, Láng, István, Schwartzberg, Lee S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943466/
https://www.ncbi.nlm.nih.gov/pubmed/29573207
http://dx.doi.org/10.1002/cam4.1388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943466/
https://www.ncbi.nlm.nih.gov/pubmed/29573207
http://dx.doi.org/10.1002/cam4.1388

Ejemplares similares